Using Table 1, the three-cycle estimate for mesothelin targeting thorium-227 conjugate direct drug ($40,116) and dosimetry ($14,175) costs totals $54,291 (in 2020 U.S. dollars), which could ultimately be less than the median six cycles ($106,200) of PARP inhibitor treatment (i.e., as used in one trial for women with recurrent ovarian cancer [13]). This evidence concerns the gene MSLN and ovarian cancer.